ArticleThe Journal of experimental medicine2005
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 69 citations in OpenAlex.
- NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.International journal of molecular sciences · 2026Review
- Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.Frontiers in immunology · 2022Review
- Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling.Journal for immunotherapy of cancer · 2021Article
- Review
- Prospects for NK Cell Therapy of Sarcoma.Cancers · 2020Review
- NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.Molecular therapy oncolytics · 2020Article
- Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.Biomolecules · 2020Review
- E1A oncogene induced sensitization to NK cell induced apoptosis requires PIDD and Caspase-2.Cell death discovery · 2019Article
- Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.International journal of molecular sciences · 2018Review
- Oncolytic measles virus enhances antitumour responses of adoptive CD8Scientific reports · 2017Article
- Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8Cancer immunology research · 2017Article
- Article
- Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.Oncotarget · 2016Article
- Immunosurveillance and immunotherapy of tumors by innate immune cells.Current opinion in immunology · 2016Review
- Article
- Adenovirus serotype 5 E1A expressing tumor cells elicit a tumor-specific CD8+ T cell response independent of NKG2D.Results in immunology · 2015Article
- Possible role of arginase-1 in concomitant tumor immunity.PloS one · 2014Article
- Molecular Bases for the Regulation of NKG2D Ligands in Cancer.Frontiers in immunology · 2014Review
- Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1.Molecular cancer · 2013Article
- Regulation of ligands for the NKG2D activating receptor.Annual review of immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The expression of the Adenovirus serotype 5 (Ad5) E1A oncogene sensitizes tumor cells to natural killer (NK) cell-mediated killing and tumor rejection in vivo. These effects are dependent on the ability of E1A to bind the transcriptional coadaptor protein p300. To test the hypothesis that E1A up-regulates ligands recognized by the NKG2D-activating receptor, we stably transfected the highly tumorigenic mouse fibrosarcoma cell line MCA-205 with Ad5-E1A or a mutant form of E1A that does not interact with p300 (E1A-Deltap300). Ad5-E1A, but not E1A-Deltap300, up-regulated the expression of the NKG2D ligand retinoic acid early inducible (RAE)-1, but not murine ULBP-like transcript 1, another NKG2D ligand, in four independently derived MCA-205 transfectants. The up-regulation of RAE-1 by E1A targeted MCA-205 tumor cells to lysis by NK cells, resulting in NKG2D-dependent tumor rejection in vivo. Moreover, the up-regulation of NKG2D ligands by E1A was not limited to mouse tumor cells, as E1A also increased the expression of NKG2D ligands on primary baby mouse kidney cells, human MB435S breast cancer cells, and human H4 fibrosarcoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.